Drugs made from blood plasma, blood derivative products are used in the treatment of numerous diseases, such as hemophilia or immunodeficiency. Their use is often associated with life threatening situations. These highly sensitive products represent a market nearing 10 billion dollars a year, with a steady growth of approximately 10%. Involved in this sector for the past twenty years, SGD Pharma has worked with the main companies and thus developed a high-level expertise to manufacture over 100 million vials specifically dedicated to these derivatives each year.

These vials, distributed in Europe, the US, China and Australia, are subjected to higher quality control scrutiny. And, of course, they have to always be available. In order to ensure proper availability, SGD Pharma has implemented a specific supply chain management making sure that there is always emergency stock at hand… a vital guarantee in a sector where such issues can often be critical.